BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lexicor Medical Technologies, Inc. Release: Multi-Center Study Evaluates Use Of NeuroLex Indicator Report Service(SM) In ADHD Assessment


10/19/2005 5:13:18 PM

AUGUSTA, Ga., Oct. 6 /PRNewswire/ -- A multi-center study, led by Dr. Humberto Quintana of the Louisiana State University Health Science Center, shows that a new process using quantitative electroencephalogram (qEEG) can improve a physician's ability to correctly diagnose Attention Deficit Hyperactivity Disorder (ADHD). The study was conducted using the NeuroLex Indicator Report Service(SM) from Lexicor Medical Technology, Inc. Lexicor sponsored the study.

(Photo: http://www.newscom.com/cgi-bin/prnh/20051006/CLTH014)

"In medicine, diagnosis usually guides treatment," Dr. Quintana said. "Diagnosis in child psychiatry often varies significantly depending on the child psychiatrist or mental health professional that sees the child. Since child psychiatry lacks significant objective measures, it may be possible that out of ten child psychiatrists seeing a child, only five will agree on an ADHD diagnosis. Arriving at the wrong diagnosis may mean that the wrong, or inappropriate, treatment is given. The study demonstrates that the NeuroLex(SM) Report Service gives the doctor an objective, biological tool to aid in the diagnosis of ADHD."

Based on these findings, Lexicor has filed for 510K clearance from the FDA to market the NeuroLex(SM) service as a diagnostic medical device.

"The NeuroLex(SM) Indicator Report for ADHD is the first practical, scientifically-validated, objective and non-invasive assessment aid based upon biological indicators rather than upon subjective pencil and paper tests," states Vincient J. Colwell, Ph.D., senior vice president, clinical operations and research at Lexicor, "In fact, our research shows that classification accuracy of the report correlates very highly to the current "Gold Standard" for assessment.

The current "Gold Standard" for diagnosing ADHD is a comprehensive clinical evaluation based on DSM-IV criteria. When conducted properly, these evaluations take up to four hours to complete. Dr. Quintana's study compared qEEG scans (the NeuroLex(SM), specifically) to a Standard Psychiatric Diagnostic Evaluation (using the K-SADS-PL, CGI-Severity, Clinical Global Assessment Scale {CGAS} and the Conners' and ADHD Rating Scales). The results found overall classification accuracy greater than 90 percent.

The study shows that "all primary care medical professionals can have access to the same level of clinical assurance currently only available to a select few," Colwell added. "This will significantly improve the quality of care for patients with attention problems by minimizing testing variability in real world settings. In addition, the report service is effective in aiding the assessment of ADHD in both hyperactive and inattentive subtypes. While this technology is not a panacea, it is an important tool for the primary care physician."

During the NeuroLex(SM) Report process, digital qEEG data from a patient are collected by a qualified technician in a doctor's office. These digital qEEG data are then transmitted securely via the Internet to Lexicor. The patient's information is analyzed for biological markers for ADHD. This comparison allows the doctor to determine whether or not a patient shows the brain wave pattern most associated with ADHD. The doctor uses the information provided by the NeuroLex(SM) Indicator Report in conjunction with other assessment tools and clinical judgment to determine whether or not the patient suffers from ADHD. The procedure takes 20 to 30 minutes and does not cause any significant side effects or major discomfort -- head hair has to be washed or cleansed of gel before electrode placement.

For more information about Lexicor and the NeuroLex(SM) Indicator Report for ADHD, visit www.lexicor.com.

About Lexicor

For more than 13 years, Lexicor has been the leader in the field of digital EEG data collection, management and analysis. Lexicor is the first company to offer global access to a proprietary neuro-assessment reporting service -- the NeuroLex Indicator Report Service(SM). For more information, contact Lexicor at 888-LEXICOR or visit www.lexicor.com.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20051006/CLTH014AP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comLexicor Medical Technology, Inc.

CONTACT: Mike Crisp of Lexicor Medical Technology, Inc., +1-864-298- 1430,or crisp@hendersonadv.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES